National Comprehensive Cancer Network



About NCCN

NCCN Updates: Guidelines, Drugs & Biologics, Order Templates

The NCCN Clinical Practice Guidelines in Oncology™ for Multiple Myeloma updated

In the updated NCCN Multiple Myeloma Guidelines, bortezomib plus dexamethasone is now a category 1 option as induction therapy for transplant candidates. Bortezomib, doxorubicin, and dexamethasone is now upgraded to category 1 from a category 2B option, as induction therapy for transplant candidates based on interim data from the HOVON-65/ GMMG-HD4 phase III trial. Bortezomib in combination with thalidomide and dexamethasone is now a category 1 option as induction therapy for transplant candidates.

Lenalidomide in combination with dexamethasone is now a category 1 recommendation in the NCCN Guidelines as an induction therapy option for both transplant and non-transplant candidates. Older regimens, including dexamethasone as a single agent, thalidomide with dexamethasone for both transplant and non-transplant candidates, DVD (liposomal doxorubicin, vincristine, and dexamethasone) for transplant candidates, and VAD (vincristine, doxorubicin, and dexamethasone) for non-transplant candidates, that were previously category 2A recommendations are now category 2B.

For the complete updated version of the NCCN Clinical Practice Guidelines in Oncology™, please visit NCCN.org.

Quick Links


About NCCN| NCCN Member Institutions| Patient Resources| NCCN Foundation| Privacy Policy| Legal Notices| Contact Us

275 Commerce Drive, Suite 300, Fort Washington, PA 19034 • 215.690.0300 • Fax: 215.690.0280
Copyright © 2013 National Comprehensive Cancer Network, All Rights Reserved